5 FDA Decisions to Watch for Through June 2023 : comparemela

From a novel topical gene therapy to a multi-pathway targeting HF drug, the second quarter of 2023 is laden with interesting regulatory decisions.

Related Keywords

United States , American , Iapocec Mavacamten , Paul Feuerstadt , Kunzmannk Sotagliflozin , Theodore Leng , Deepak Bhatt , Professor Of Ophthalmology At Stanford University , Alexion Pharmaceuticals , American Academy Of Dermatology , Sotagliflozin Lexicon Pharmaceuticals For Heart Failure , American College Of Cardiology , Drug Administration , Yale School Of Medicine , Bristol Myers Squibb , Seres Therapeutics , Recurrent Clostridioides , Yale School , Krystal Biotech , Dystrophic Epidermolysis Bullosa , American Academy , Lexicon Pharmaceuticals , Heart Failure , New Drug Application , Mount Sinai Heart , Valentin Fuster Professor , Cardiovascular Medicine , Mount Sinai Icahn School , American College , Hypertrophic Cardiomyopathy , Wet Age Related Macular Degeneration , Diabetic Macular Edema , Biologics License Application , Associate Professor , Stanford University , Preventsc Difficile Recurrences , Published October , Newc Difficile Treatment , Published December , Dystrophic Epidermolysis , Published January , Published March , Treat Heart , Kidney Disease Patients , Published April , Accepts Supplemental New Drug Application , Septal Reduction , Reduces Eligibility , Obstructive Hypertrophic , Published February , Buy In Is Still Lacking ,